Cargando…
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
Mesalamine and its derivatives are effective and well-tolerated therapies for ulcerative colitis. However, patient adherence to traditional mesalamine-based therapy is poor, and is often limited by heavy pill burdens and frequent dosing intervals. This can lead to ineffective disease control, impair...
Autores principales: | Zandman, Daniel B, Peppercorn, Mark A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778435/ https://www.ncbi.nlm.nih.gov/pubmed/19936149 |
Ejemplares similares
-
Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007) -
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012) -
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013) -
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011) -
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
por: Doherty, Glen A, et al.
Publicado: (2009)